{"id":61694,"date":"2025-08-06T07:05:27","date_gmt":"2025-08-06T05:05:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/"},"modified":"2025-08-06T07:05:27","modified_gmt":"2025-08-06T05:05:27","slug":"lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/","title":{"rendered":"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Lysoway Therapeutics, Inc.<\/b>, a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Support comes from MJFF\u2019s Parkinson\u2019s Disease Therapeutics Pipeline Program<\/i><\/a>, which focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson\u2019s disease. Lysoway Therapeutics funding of $2.93 million will support the preclinical and translational development of Lysoway\u2019s novel, highly brain-penetrant small molecule TRPML1 agonist.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe study aims to investigate whether activating TRPML1 by a novel, small molecule modulator, will enhance the lysosomal membrane calcium ion channel to restore lysosomal function and help with clearance of alpha-synuclein, the protein that is linked to the disease.<\/p>\n

\n\u201cWe are honored to receive this generous grant from The Michael J. Fox Foundation,\u201d said Valerie Cullen, PhD<\/b>, Principal Investigator and SVP of Research and Translation at Lysoway. \u201cTRPML1 is a high value target due to its pivotal role in sensing and responding to cellular stress. By activating this ion channel, we can engage multiple beneficial pathways that restore autophagy\/lysosomal homeostasis and bolster cellular resilience. Our lead development candidate is both orally bioavailable and highly brain-penetrant, offering strong potential to modify disease progression in Parkinson\u2019s Disease.\u201d<\/p>\n

\nYongchang Qiu, PhD<\/b>, Founder and Chief Executive Officer of Lysoway Therapeutics, added \u201cThis funding underscores growing confidence in TRPML1 as a compelling target for Parkinson\u2019s disease. It will allow us to accelerate development of our lead TRPML1 agonist and to establish key biomarkers for target engagement, with the goal of initiating first-in-human clinical trials early next year.\u201d<\/p>\n

\nAbout <\/strong>Lysoway Therapeutics<\/b>, Inc.
\n
<\/strong>Based in Cambridge, MA, Lysoway Therapeutics is a leader in developing therapeutically viable lysosomal ion channel modulators. The company is advancing a pipeline of small molecule activators targeting these channels to treat neurodegenerative diseases. Learn more at www.lysoway.com<\/i><\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contact: Info@lysoway.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Lysoway Therapeutics, Inc., a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Support comes from MJFF\u2019s Parkinson\u2019s Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61694","6":"format-standard","7":"category-industry"},"yoast_head":"\nLysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Lysoway Therapeutics, Inc., a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Support comes from MJFF\u2019s Parkinson\u2019s Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-06T05:05:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250805132586\/en\/2545316\/22\/Lysoway_rgb.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease\",\"datePublished\":\"2025-08-06T05:05:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/\"},\"wordCount\":351,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250805132586\\\/en\\\/2545316\\\/22\\\/Lysoway_rgb.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/\",\"name\":\"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250805132586\\\/en\\\/2545316\\\/22\\\/Lysoway_rgb.jpg\",\"datePublished\":\"2025-08-06T05:05:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250805132586\\\/en\\\/2545316\\\/22\\\/Lysoway_rgb.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250805132586\\\/en\\\/2545316\\\/22\\\/Lysoway_rgb.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/","og_locale":"en_US","og_type":"article","og_title":"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Lysoway Therapeutics, Inc., a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Support comes from MJFF\u2019s Parkinson\u2019s Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-06T05:05:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250805132586\/en\/2545316\/22\/Lysoway_rgb.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease","datePublished":"2025-08-06T05:05:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/"},"wordCount":351,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250805132586\/en\/2545316\/22\/Lysoway_rgb.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/","url":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/","name":"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250805132586\/en\/2545316\/22\/Lysoway_rgb.jpg","datePublished":"2025-08-06T05:05:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250805132586\/en\/2545316\/22\/Lysoway_rgb.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250805132586\/en\/2545316\/22\/Lysoway_rgb.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61694"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61694\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}